Assembly Biosciences Statistics
Share Statistics
Assembly Biosciences has 6.36M shares outstanding. The number of shares has increased by -90.36% in one year.
| Shares Outstanding | 6.36M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 2.91% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 4.47M |
| Failed to Deliver (FTD) Shares | 75 |
| FTD / Avg. Volume | 0.22% |
Short Selling Information
The latest short interest is 16.42K, so 0.26% of the outstanding shares have been sold short.
| Short Interest | 16.42K |
| Short % of Shares Out | 0.26% |
| Short % of Float | 0.37% |
| Short Ratio (days to cover) | 0.41 |
Valuation Ratios
The PE ratio is -0.74 and the forward PE ratio is -2.39.
| PE Ratio | -0.74 |
| Forward PE | -2.39 |
| PS Ratio | 6.29 |
| Forward PS | 2.6 |
| PB Ratio | 1.1 |
| P/FCF Ratio | 2 |
| PEG Ratio | n/a |
Enterprise Valuation
Assembly Biosciences Inc. has an Enterprise Value (EV) of 27.54M.
| EV / Earnings | -0.45 |
| EV / Sales | 3.85 |
| EV / EBITDA | -0.43 |
| EV / EBIT | -0.43 |
| EV / FCF | 1.22 |
Financial Position
The company has a current ratio of 3.41, with a Debt / Equity ratio of 0.
| Current Ratio | 3.41 |
| Quick Ratio | 3.49 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.49% and return on capital (ROIC) is -148.9%.
| Return on Equity (ROE) | -1.49% |
| Return on Assets (ROA) | -0.45% |
| Return on Capital (ROIC) | -148.9% |
| Revenue Per Employee | 110.20K |
| Profits Per Employee | -941.97K |
| Employee Count | 65 |
| Asset Turnover | 0.05 |
| Inventory Turnover | -15.3 |
Taxes
| Income Tax | 33.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 69.99% in the last 52 weeks. The beta is 0.59, so Assembly Biosciences 's price volatility has been higher than the market average.
| Beta | 0.59 |
| 52-Week Price Change | 69.99% |
| 50-Day Moving Average | 16.38 |
| 200-Day Moving Average | 14.96 |
| Relative Strength Index (RSI) | 43.49 |
| Average Volume (20 Days) | 33.66K |
Income Statement
In the last 12 months, Assembly Biosciences had revenue of $7.16M and earned -$61.23M in profits. Earnings per share was $-13.38.
| Revenue | 7.16M |
| Gross Profit | -41.74M |
| Operating Income | -64.65M |
| Net Income | -61.23M |
| EBITDA | -64.20M |
| EBIT | -64.65M |
| Earnings Per Share (EPS) | -13.38 |
Balance Sheet
The company has $19.84M in cash and $2.34M in debt, giving a net cash position of $17.50M.
| Cash & Cash Equivalents | 19.84M |
| Total Debt | 2.34M |
| Net Cash | 17.50M |
| Retained Earnings | -785.75M |
| Total Assets | 100.26M |
| Working Capital | 56.58M |
Cash Flow
In the last 12 months, operating cash flow was $22.74M and capital expenditures -$255.00K, giving a free cash flow of $22.49M.
| Operating Cash Flow | 22.74M |
| Capital Expenditures | -255.00K |
| Free Cash Flow | 22.49M |
| FCF Per Share | 4.91 |
Margins
Gross margin is -582.67%, with operating and profit margins of -902.5% and -854.78%.
| Gross Margin | -582.67% |
| Operating Margin | -902.5% |
| Pretax Margin | -854.32% |
| Profit Margin | -854.78% |
| EBITDA Margin | -896.22% |
| EBIT Margin | -902.5% |
| FCF Margin | 313.95% |
Dividends & Yields
ASMB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -87.17% |
| FCF Yield | 23.05% |
Analyst Forecast
The average price target for ASMB is $35, which is 128% higher than the current price. The consensus rating is "Hold".
| Price Target | $35 |
| Price Target Difference | 128% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Feb 12, 2024. It was a backward split with a ratio of 1:12.
| Last Split Date | Feb 12, 2024 |
| Split Type | backward |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | -11.17 |
| Piotroski F-Score | 4 |